Suppliers / Assurgen Pharma

Assurgen Pharma

India 38 employees Updated 9 July 2026

Assurgen Pharma is an API manufacturer based in India. It holds 8 valid CEPs across a filed portfolio of 7 molecules. Its GMP standing is certified by EMA. Customs aggregates show $3.6M of exports covering 39 molecules to 11 destinations in 2025.

0
active US DMFs
8
valid CEPs
2
registered plants
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
Visakhapatnam, India Not on file
Lalamkoduru Village, India Not on file

What they file, and where

Molecule Regulators Docs
Sodium Valproate EDQM 2
Allopurinol EDQM 1
Oxcarbazepine EDQM 1
Pantoprazole EDQM 1
Tadalafil EDQM 1
Valproic Acid EDQM 1
Verapamil EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 2

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $532K 5
2025 Not reported $3.6M 11
2024 Not reported $2.3M 9
2023 Not reported $2.4M 13

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Assurgen Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts